Sam Altman’s $180m anti-ageing bet on bold longevity plan to extend lifespan

For years, Silicon Valley treated ageing as a background fact of life rather than a technical problem. Wealth from the AI boom is now flowing into laboratories studying cells, proteins, and human lifespan, with some of the technology industry’s biggest names placing unusually large bets on medicine.